Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
| Dec 25 | Dec 25 | Dec 24 | Dec 23 | Dec 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 65.32M | - | $ 67.64M | $ 79.20M | $ 86.16M |
| Gross Profit | $ 65.32M | - | $ 67.64M | $ 79.20M | $ 86.16M |
| Operating Income | $ -85.35M | - | $ -121.69M | $ -137.21M | $ -123.84M |
| EBITDA | $ -70.78M | - | $ -104.51M | $ -123.48M | $ -119.22M |
| Net Income | $ -81.89M | - | $ -116.05M | $ -133.82M | $ -121.75M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 188.86M | $ ― | $ 248.19M | $ 369.91M | $ 249.23M |
| Total Assets | $ 280.73M | - | $ 376.65M | $ 462.27M | $ 380.59M |
| Total Debt | $ 201.06M | - | $ 226.06M | $ 222.44M | $ 26.69M |
| Net Debt | $ 168.76M | - | $ 188.82M | $ 137.05M | $ -17.31M |
| Total Liabilities | $ 216.01M | - | $ 247.84M | $ 245.54M | $ 59.26M |
| Stockholders' Equity | $ 64.72M | $ ― | $ 128.81M | $ 216.74M | $ 321.33M |
| Cash Flow | |||||
| Free Cash Flow | $ -32.17M | - | $ -96.71M | $ -112.21M | $ -86.91M |
| Operating Cash Flow | $ -19.27M | - | $ -78.76M | $ -103.15M | $ -84.78M |
| Investing Cash Flow | $ 40.35M | - | $ 58.23M | $ -53.58M | $ 54.90M |
| Financing Cash Flow | $ -26.62M | - | $ -27.63M | $ 198.13M | $ 20.03M |